J&J ends two CAR-T programs Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 1 May, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one

Spotlight Bioregnum The R&D 15: The stakes needed to play in the world's biggest drug research groups require very deep pockets

news Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut J&J axes pair of CAR-T therapies for lymphoma, citing evolving market Peer Review Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit FDA's oncology advisors vote against 'new paradigm' in AstraZeneca breast cancer trial

May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

Endpoints Pharma House panel calls for banning China data from FDA drug trial applications Court dismisses part of Lilly lawsuit against compounder Empower, but some claims can proceed Bristol Myers' Krazati fails confirmatory trial in colorectal cancer, putting approval at risk Supreme Court questions how far generics makers can go when marketing 'skinny label' drugs

in case you missed it 1. Updated: Analysts focus on three pipeline programs in pivotal year for Bristol Myers 2. Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s 3. Novartis unveils North Carolina factory as final new build in $23B US expansion 4. News Briefing Avalyn's upsized IPO; Alector ends another study in GSK partnership; Teva's $700M buy 5. Brain scans reveal 3 ADHD subtypes, including a more extreme form